57474 Federal Register / Vol. 75, No. 182 / Tuesday, September 21, 2010 / Notices 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, T32 

Review. 

Date: September 21, 2010. 

Time: 5 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Alexandria Old Town, 1767 

King Street, Alexandria, VA 22314. 

Contact Person: Sergei Radaev, PhD, 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 6116 Executive Boulevard, 

Room 8113, Bethesda, MD 20892. 301–435– 

5655. sradaev@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to scheduling 

conflicts. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Preclinical 

Toxicology Study of Drugs Developed for 

Cancer and Other Diseases. 

Date: September 23, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Zhiqiang Zou, MD, PhD, 

Scientific Review Officer, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Blvd., Room 8055A, MSC 8329, 

Bethesda, MD 20852. zouzhiq@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to scheduling 

conflicts. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, 

Therapeutic Strategies for Cancer. 

Date: October 14–15, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Majed M. Hamawy, MBA, 

PhD, Scientific Review Officer, Research 

Programs Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 6116 Executive Boulevard, 

Room 8135, Bethesda, MD 20852. 301–594– 

5659. mh101v@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Cellular & 

Tissue Biology II P01. 

Date: October 19, 2010. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6116 

Executive Boulevard, Room 8018, Rockville, 

MD 20852. (Telephone Conference Call.) 

Contact Person: Caron A. Lyman, PhD, 

Scientific Review Officer, Research Programs 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, 6116 

Executive Blvd, Room 8119, Bethesda, MD 

20892–8328. 301–451–4761. lymanc@mail.

nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Small 

Grants Program for Cancer Epidemiology. 

Date: October 28–29, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Legacy Hotel and Meeting Center, 

1775 Rockville Pike, Rockville, MD 20852. 

Contact Person: Joyce C. Pegues, BS, BA, 

PhD, Scientific Review Officer, Special 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 6116 Executive Boulevard, 

Room 7149, Bethesda, MD 20892–8329. 301– 

594–1286. peguesj@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Small 

Grants Behavioral Research in Cancer 

Control. 

Date: November 15–16, 2010. 

Time: 7 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Legacy Hotel and Meeting Center, 

1775 Rockville Pike, Rockville, MD 20852. 

Contact Person: Gerald G. Lovinger, PhD, 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8101, 

Bethesda, MD 20892–8329. 301/496–7987. 

lovingeg@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 15, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–23545 Filed 9–20–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

President’s Cancer Panel. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: President’s Cancer 

Panel. 

Date: October 26, 2010. 

Time: 8 a.m. to 4 p.m. 

Agenda: The Future of Cancer Research: 

Accelerating Scientific Innovation. 

Place: Chemical Heritage Foundation, 315 

Chestnut Street, Philadelphia, PA 19106. 

Contact Person: Abby B. Sandler, PhD, 

Executive Secretary, Chief, Institute Review 

Office, Office of the Director, 6116 Executive 

Blvd., Suite 220, MSC 8349, National Cancer 

Institute, NIH, Bethesda, MD 20892–8349, 

(301) 451–9399, sandlera@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: deainfo.nci.

nih.gov/advisory/pcp/pcp.htm, where an 

agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 15, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–23543 Filed 9–20–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Cardiovascular and Renal Drugs 

Advisory Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Cardiovascular 

and Renal Drugs Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on October 18, 2010, from 8 a.m. 

to 5 p.m. 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 182 / Tuesday, September 21, 2010 / Notices 57475 

Location: The Marriott Inn and 

Conference Center, University of 

Maryland University College, 3501 

University Boulevard East, Adelphi, 

MD. The conference center telephone 

number is 301–985–7300. 

Contact Person: Elaine Ferguson, 

Center for Drug Evaluation and 

Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., WO31–2417, Silver Spring, MD 

20993–0002, 301–796–9001, FAX: 301– 

847–8540, email: elaine.ferguson@fda.

hhs.gov, or FDA Advisory Committee 

Information Line, 1–800–741–8138 

(301–443–0572 in the Washington, DC 

area), code 3014512533. Please call the 

Information Line for up-to-date 

information on this meeting. A notice in 

the Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly 

enough to provide timely notice. 

Therefore, you should always check the 

agency’s Web site and call the 

appropriate advisory committee hot 

line/phone line to learn about possible 

modifications before coming to the 

meeting. 

Agenda: On October 18, 2010, the 

committee will consider the results and 

analyses of the TREAT (Trial to Reduce 

Cardiovascular Events with Aranesp 

Therapy) study of ARANESP 

(darbepoetin alfa), manufactured by 

Amgen, Inc. This meeting is a follow-up 

to the September 2007 advisory 

committee meeting at which the 

committee discussed updated 

information on the risks and benefits of 

erythropoeisis-stimulating agents (drugs 

that stimulate production of red blood 

cells), marketed under the brand names 

ARANESP, EPOGEN, and PROCRIT, 

manufactured by Amgen, Inc., when 

used in the treatment of anemia (low red 

blood cell counts) due to chronic kidney 

failure. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/

AdvisoryCommittees/Calendar/default.

htm. Scroll down to the appropriate 

advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before October 11, 2010. 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. and 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before October 3, 2010. Time allotted 

for each presentation may be limited. If 

the number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by October 4, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Elaine 

Ferguson at least 7 days in advance of 

the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: September 15, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–23514 Filed 9–20–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Molecular, Cellular 

and Developmental Neuroscience Integrated 

Review Group; Cellular and Molecular 

Biology of Neurodegeneration Study Section. 

Date: October 14–15, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Donovan House, 1155 14th Street, 

NW., Washington, DC 20005. 

Contact Person: Laurent Taupenot, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4183, 

MSC 7850, Bethesda, MD 20892, 301–435– 

1203, taupenol@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Biobehavioral Regulation and 

Learning. 

Date: October 15, 2010. 

Time: 2:30 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Telephone Conference Call). 

Contact Person: Biao Tian, PhD, Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 3089B, MSC 7848, Bethesda, 

MD 20892, (301) 402–4411, tianbi@csr.nih.

gov. 

Name of Committee: Healthcare Delivery 

and Methodologies Integrated Review Group; 

Nursing and Related Clinical Sciences Study 

Section. 

Date: October 19–20, 2010. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: InterContinental Mark Hopkins 

Hotel, 999 California Street, San Francisco, 

CA 94108. 

Contact Person: Katherine Bent, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3160, 

MSC 7770, Bethesda, MD 20892, 301–435– 

0695, bentkn@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Collaborative: Behavioral Genetics and 

Epidemiology Linked Applications. 

Date: October 20–21, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Avenue, NW., Washington, DC 20037. 

Contact Person: Suzanne Ryan, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 


srobinson on DSKHWCL6B1PROD with NOTICES